Kornimate/medical-research-clean huggingface dataset:
orthopedic digital planning for total hip arthroplasties

Conditions: Infection of Total Hip Joint Prosthesis

Summary: preoperative planning has been carried out to allow for response preparedness . a layer technique is usually used with standard radiography .the investigators have a record of routine preoperative radiographs by standard recognized as having an advantage over the reproducibility of measurements compared with plain radiography . the toulouse hospitals have developed this technology and is part of the routine assessment of hip prothesis pre and postoperatively. the traumacad software can superimpose implants on picture archiving and communication system and evaluate digital and reproducible size of the implants and their correct position . this is to demonstrate the superiority of modern digital tools in the preoperative preparation in orthopaedics set.

modern joint replacements in orthopedic surgery allow to restore locomotion. more than 150,000 hip replacements are performed each year in france . the optimization results going restoration of the lengths of members and anatomy . preoperative planning of hip replacements optimizes the return of the hip rotation center . preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise . the recent traumacad system ( brainlab® ) allows adjustment of the scales for each patient and the virtual positioning of implants to simulate the response to the return of geometric parameters of the hip. preoperative planning by traumacad hip arthroplasties provides better restitution of limb length over conventional planning methods. the standardized radiographs being the investigators want to compare this group with a control group operated without traumacad planning and evaluating the accuracy of the software to predict implants sizes also . there is no risk to the patient with this procedure . the direct benefit is increased accuracy of surgical gesture to the patient and the reduction of mechanical problems related to leg length . earnings for the orthopedic community is the postoperative evaluation. in the long term , the prosthetic technical improvement must increase the life of prostheses with therefore lower revisions and less expenditure in terms of public health. the widespread use of automated planning and objective assessment postoperative radiographs .

Eligibility criteria:
inclusion criteria: * inclusion concerns all major patients able supported for osteoarthritis for the realization of a primary hip replacement . exclusion criteria: * minor patients * bmi greater than 35 patients * recovery or major architectural disorder surgery ( preoperative upper inequality 2 cm or dysplastic hip)
ulnar shaft fracture fixation by antegrade versus retrograde intramedullary k wires in children

Conditions: Fracture of Ulna Shaft

Summary: this study is made to see and evaluate the outcomes of treating and fixing ulnar shaft fracture in children by antegrade versus retrograde intramedullary k wires

this study is made on children with ulnar shaft fracture and treating their fracture by intramedullary k wires ,dividing them into two groups ,one of them the child ulnar fracture is reduced and fixed by intramedullary antegrade k wire and the other group the fracture is reduced and fixed by retrograde k wire ,and compare the functional, clinical and radiological outcomes between the two groups

Eligibility criteria:
inclusion criteria: * pediatric patient * aging from 4 to 15 years old * diaphyseal ulnar fracture * either isolated or combined with radius fracture (both bone). exclusion criteria: * segmental fractures * montaggia variants * gelliazzi fracture * fractures associated with radial head fracture - compound fractures * fractures with neurovascular affection

Keywords: fixation of pediatric ulna shaft fracture
satavaptan dose-ranging study in the prevention of ascites

Conditions: Ascites; Liver Cirrhosis

Summary: the primary objective is to determine the optimal dose or range of doses of sr121463b for the reduction in recurrence of ascites, when used concomitantly with a standard dose regimen of spironolactone. the secondary objective was to determine the tolerability of different fixed doses of sr121463b in cirrhotic ascites, over a 12-week treatment period. this spa study is followed by a single-blind, placebo-controlled, 40 weeks long-term safety extension (exspa). the first extension is followed by another long-term study (pasccal-1).


Eligibility criteria:
inclusion criteria: * cirrhosis of the liver confirmed by ultrasound, endoscopic examination or biochemical evidence * patients having undergone therapeutic paracentesis for the removal of ascites in the previous 24 hours with the removal of ≥4 l of fluid * patients having undergone at least 1 other therapeutic paracentesis in the previous 3 months the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: cirrhotic ascites
comprehensive disease management program in chronic obstructive pulmonary disease (copd) patients in the community

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to determine whether comprehensive disease management program combined with best care recommended in clinical guidelines, is more effective than best care alone in patients with advanced chronic obstructive pulmonary disease (copd).

the study objective is to evaluate the effectiveness of a comprehensive program among patients with advanced copd, implemented by a multi-disciplinary team. the program consists of best care recommended in clinical guidelines, combined with disease management, compared to best care only. the program will include designated copd centers operated by multi-disciplinary teams (pulmonologists, nurse practitioners, physiotherapists, social workers and dietitians). disease management will be provided in these centers by qualified designated nurses.

Eligibility criteria:
inclusion criteria: 1. age 40 years or older 2. advanced copd exclusion criteria: 1. permanent tracheostomy 2. heart failure with significant left-ventricular dysfunction 3. severe other chronic disease 4. significant cognitive impairment, drug or alcohol abuse, inability to cooperate 5. no telephone or permanent address 6. bedridden 7. refusal to use telemonitoring equipment 8. participation in another clinical trial

Keywords: chronic obstructive pulmonary disease disease management pulmonary rehabilitation quality of life
the effect of intrauterine lidocaine infusion and oral tramadol on pain during diagnostic office hysteroscopy

Conditions: Hysteroscopy

Summary: the purpose of this study is to compare the effectiveness of tramadol and intrauterine lidocaine infusion in reducing pain during outpatient diagnostic hysteroscopy in postmenopausal women.

the purpose of this study is to compare the effectiveness of tramadol and intrauterine lidocaine infusion in reducing pain during outpatient diagnostic hysteroscopy in postmenopausal women. postmenopausal women undergoing outpatient hysteroscopy in cairo university will be divided into three groups, the first group will receive tramadol 5mg 1 hour before the procedure, the second group will receive 20 ml lidocaine in 1000 ml normal saline infusion during the procedure, and the third will receive a placebo. a visual analog scale will assess pain.

Eligibility criteria:
inclusion criteria: * menopausal patients with an indication for office hysteroscopy (postmenopausal bleeding or abnormal ultrasound findings) * consent to the procedure exclusion criteria: * positive chlamydia culture. * patients who have an allergy to local anesthesia or tramadol. * a previous adverse reaction to any of the drugs used in the study. * patients were receiving any form of analgesia or current use of monoamine oxidase inhibitors. * nulliparous patients and patients with cervical pathology, retroverted uterus (detected by transvaginal ultrasound), and previous cervical surgery. * patients who have severe vaginal bleeding.
study to evaluate efficacy and safety of histrelin subdermal implant in men with advanced prostate cancer

Conditions: Prostate Cancer; Adenocarcinoma of the Prostate

Summary: objective was to evaluate the efficacy and safety of the histrelin acetate subdermal implant (originally versus lupron depot-3 month) in male patients with advanced prostate cancer during 52 weeks of treatment with the implant. after consultation w/ fda, design was modified to eliminate the lupron arm and continued the study as an open-label non-randomized study. primary endpoint was testosterone suppression, as assessed by the percent of patients whose testosterone indicated chemical castration levels (\<=50 ng/dl) through 52 weeks of treatment with an implant.

other outcome measures included serum levels of lh, psa, as well as non-clinical assessments, eg, who performance status, pain level assessment, and quality of life questionnaires. safety was evaluated via adverse events, vital signs, clinical laboratory outcomes, physical examinations, and ecgs. local tolerability outcomes were also evaluated. an extension period for the study included annual replacement of the implant until the implant was approved by the fda (october 12, 2004). efficacy and safety were followed during the extension period.

Eligibility criteria:
key inclusion criteria: * male age 45 or older * histologically confirmed adenocarcinoma of the prostate * disease staging iii or iv * clinical indication for androgen suppression therapy * serum testosterone at least 150 ng/dl at screening * who performance scale 0 to 3 * life expectancy of at least one year key exclusion criteria: * bilateral orchiectomy * prior androgen-ablative therapy within past year * second malignancy with 5 years (except adequately treated non-melanomatous skin cancer or superficial bladder cancer) * spinal cord compression

Keywords: prostate cancer, psa
safety and efficacy of restylane lidocaine and restylane perlane lidocaine for facial augmentation in asian population

Conditions: Healthy Volunteers

Summary: the purpose of this study is to evaluate the safety and efficacy of restylane lidocaine and restylane perlane lidocaine after the first and second treatment when used for facial augmentation in asian population.


Eligibility criteria:
inclusion criteria: * subjects intent to undergo facial filler treatment for either volume loss or contouring * subjects requiring treatment in two to four of pre-defined areas in the face (upper cheeks, nasolabial folds, temples, nose and chin) * require 3-5 ml of investigational products to achieve a clinically meaningful improvement in appearance * facial appearance as han chinese * non-pregnant, non-breast feeding female * signed informed consent exclusion criteria: * previous facial surgery (e.g. rhinoplasty) or permanent implant in the area to be treated. * history of chronic sinusitis or rhinitis (only applicable for subjects injected in the nose). * subjects who needs to use heavy glasses during the study (only applicable for subjects injected in the nose). * previous tissue augmenting therapy or contouring with permanent filler or fat injection in the facial area. * previous treatment with hyaluronic acid (ha) fillers or restylane skinboosters in the facial area within 12 months before treatment. * previous treatment with non-ha fillers such as caha (calcium hydroxylapatite) or plla (poly l-lactic acid) within 24 months before treatment. * previous revitalization with neurotoxin in the facial area within six (6) months before treatment. * previous tissue revitalization treatment with laser or light, mesotherapy, chemical peeling or dermabrasion in the facial area within six (6) months before treatment. * any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may interfere with the outcome of the study).
patient-centered intervention to reduce cancer patients' financial toxicity

Conditions: Gynecologic Cancer; Colorectal Cancer; Lung Cancer

Summary: the purpose of this study is to incorporate feedback from cancer patients and providers to adapt, implement, and test an intervention. the intervention aims to prompt screening for financial distress, facilitate discussions about care costs with cancer patients, support health insurance selection, and ultimately reduce cancer patients' financial toxicity associated with cancer care.


Eligibility criteria:
eligibility criteria for i can pic arm only: inclusion criteria: * 18 years of age or older * must have been diagnosed with colorectal cancer, lung cancer, or gynecologic cancer \< 5 months ago and be patients of one of the 15 providers * this cancer diagnosis must be the first and primary diagnosis exclusion criteria: * not able to read and understand english * cannot give informed consent due to cognitive or emotional barriers
phase iii altu-135 cp safety trial

Conditions: Exocrine Pancreatic Insufficiency

Summary: this is an open-label, single-arm clinical study investigating the long-term safety of altu-135 treatment in chronic pancreatitis (cp) patients with exocrine pancreatic insufficiency (pi).


Eligibility criteria:
inclusion criteria: * females of childbearing potential must be willing to use birth control * fecal elastase levels \< 100 micrograms per gram (µg/g) stool measured at screening * able to perform the testing and procedures required for the study, as judged by the investigator * diagnosis of chronic pancreatitis or status post pancreatectomy diagnosis of chronic pancreatitis is based upon at least one of the following: * endoscopic retrograde pancreatography, magnetic resonance cholangiopancreatography (mrcp) or endoscopic ultrasound demonstrating ductal changes consistent with chronic pancreatitis * abnormal secretin pancreatic function test with a peak bicarbonate concentration \< 75 milliequivalents per liter (meq/l) * presence of pathognomic pancreatic calcifications * pathology proven chronic pancreatitis on surgical specimens exclusion criteria: * pregnancy, breastfeeding or of childbearing potential and not willing to use methods of birth control during the study * history of liver transplant * liver transaminases \>3x upper limit normal (uln) or total bilirubin \>1.5x uln at screening or at baseline (except for patients with gilbert's syndrome) * participation in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to screening * any condition that the investigator believes would interfere with the intent of this study or would make participation not in the best interest of the patient * history of pancreatic cancer * diagnosis of cystic fibrosis * active alcohol or drug abuse * presence of any medical condition that is likely to preclude survival for 12 months * demonstrated unlikely to comply with protocol requirements or complete the study

Keywords: chronic pancreatitis pancreatectomy
influence of environmental factors and schizophrenia

Conditions: Patients With Schizophrenia; Relatives

Summary: schizophrenia is a chronic and severe mental disorder with a lifetime prevalence of about 1 per cent, the symptoms can be very disabling and causing a heavy medical and socioeconomic. there are significant variations from one population to another. clinical manifestations of schizophrenia (symptoms, evolution, severity of disability) are highly variable. this variability, both epidemiological and clinical, is due to genetic and environmental factors. environmental factors may be either risk factors or modifying factors (changing clinical presentation but do not alter the risk of disease) for schizophrenia. environmental risk factors have been identified (eg: urbanity, cannabis, migration), but the investigators don't know neither the components directly responsible, nor the mechanisms by which they increase the risk of schizophrenia. to date, there is no study has systematically evaluated the role of environmental modifying factors in schizophrenia. environmental factors may be individual, unique to each person (eg cannabis, migration.), or population-based (eg ethnic density, socio-economic difficulties.) the identification/ identifying of environmental risk factors or modifiers, both individual and population, may have theoretical implications (understanding of etiopathogenic mechanisms) and practical (implementation of preventive measures). the potential effectiveness of preventive measures is even greater than the risk attributable to certain environmental factors is important. most studies on environmental factors in schizophrenia were conducted in anglo-saxon countries and northern europe, but no study of these risk factors has been conducted in france. there are important differences environment based on study populations, these results are not generalizable to other countries, including france.


Eligibility criteria:
inclusion criteria: all subjects * age \> 18 years * somatic state / condition and level of understanding (language, intellectual level) compatible with the data collection (interview, self-administered questionnaires) patients * diagnosis of schizophrenia according to dsm-iv criteria * living in catchment areas non-inclusion criteria: all subjects * not affiliated to the social security scheme * inability to provide informed consent * decompensated schizophrenic underway relatives * protective measures (tutor, curator) exclusion criteria: patients * the diagnosis of psychotic disorder is not confirmed by the synthesis of all clinical data

Keywords: schizophrenia environmental factors
study of abdominal aortic stent grafts in the treatment of infrarenal abdominal aortic aneurysms

Conditions: Abdominal Aortic Aneurysm

Summary: the vascutek anaconda™ stent graft system for repair of abdominal aortic aneurysms (aaa) is the subject of this observational study. 180 patients will be implanted with the anaconda™ stent graft system and will be followed-up annually for 5 years post-implant. the study will satisfy the requirements of the french national authority for health (haute autorité de santé) and the data collected will be used for reimbursement renewal.

infrarenal abdominal aortic aneurysms may be treated with the introduction of an abdominal aortic stent graft via the femoral route. this technique is commonly used in high surgical risk patients but can also be suitable under certain conditions for normal risk patients. abdominal aortic stent grafts, inserted via the femoral artery, are used to treat infrarenal abdominal aortic aneurysms, removing the need for an invasive surgical procedure. the aim of this observational study is to evaluate the long-term (5 year) benefits of the technique by documenting the overall mortality, complications (endoleak, migration), rate of surgical conversion, progression and rupture of the aneurysm in a cohort of patients who are representative of the treated population under real conditions of use.

Eligibility criteria:
inclusion criteria: * any patient implanted with the vascutek anaconda™ stent graft system for the treatment of a non-ruptured infrarenal abdominal aortic aneurysm (aaa) exclusion criteria: * patients for whom clinical follow-up is impossible and cannot return for check-up visits
study of sleep inertia in major depressive disorder by the psychomotor vigilance task

Conditions: Major Depression; Sleep Inertia

Summary: the study population comprises three groups of 30 analyzable participants: patients with sleep inertia and major depressive disorder, patients with major depressive disorder but without sleep inertia, and controls without mood disorders or sleep inertia. controls will be patients referred to the sleep disorders and acupuncture unit for polysomnography as part of the screening process for a sleep disorder. only controls presenting an apnea-hypopnea index \< 15/h, a periodic leg movements index during sleep \< 15/h and a total sleep time ≥ 6 hours on the video-polysomnography will be analyzed.


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * ability to understand, write and read french inclusion criteria for patients with major depression * diagnosis of depression according to dsm-5 criteria * suspicion of a sleep disorder requiring polysomnographic screening * score for ihss items 3 and 4 * score ≥ 1 for group with sleep inertia * score = 0 for the group without sleep inertia inclusion criteria for controls * no complaints of sleep inertia (score = 0 on ihss items 3 and 4) * no excessive daytime sleepiness (epworth sleepiness scale score ≤10), * no depressive symptoms (hospital anxiety depression scale score \< 8 on items 2, 4, 6, 8, 10, 12, 14). exclusion criteria: * the patient is participating in an interventional study * the patient is under safeguard of justice or state guardianship * unweaned from the following medications for at least 5 half-lives prior to inclusion: wake-promoting or psychostimulant drugs (modafinil, methylphenidate, mazindol, amphetamine, pitolisant, solriamfetol, sodium oxybate), neuroleptics, hypnotics, antidepressants, anxiolytics, antiepileptics, budipine, dopamine agonist and antagonist antiemetics (except domperidone), opiates, gabapentin, pregabalin, benzodiazepines, z-hypnotics (zolpidem and zopiclone), monoamine oxidase inhibitors, catechol-o-methyltransferase or sedative antihistamines. * patients with central nervous system diseases: parkinson's disease, mild cognitive impairment and dementia, progressive supranuclear palsy, multisystem atrophy, huntington's chorea, amyotrophic lateral sclerosis, epilepsy, history of head trauma with loss of consciousness. * patients with a malignant neoplastic disease requiring therapeutic treatment in the 12months prior to the screening visit * other medical or psychiatric illnesses (with the exception of depression in he depression group) which, in the investigator's opinion, could interfere with the study. * history of suicide attempt (including failed attempt), or suicidal ideation in the past month * chronic alcohol consumption or drug abuse in the previous 6 months * sleep-wake circadian rhythm disorders and presence of sleep insufficiency according to icsd-3 criteria * pregnant, parturient or breast-feeding women.

Keywords: psychomotor vigilance task